Biotechnology

SHANGHAI SERUM BIO-TECHNOLOGY

SHANGHAI SERUM BIO-TECHNOLOGY released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 27.09 M, actual EPS CNY 0.01

SHANGHAI SERUM BIO-TECHNOLOGY to Release FY2026 Q1 Earnings on April 25 After-Market (BJT)

Shanghai Serum Bio-Technology to Release FY2025 Earnings on April 25 Pre-Market BJT

SHANGHAI SERUM BIO-TECHNOLOGY released FY2025 Q4 earnings on February 26 Pre-Market (BJT), actual revenue CNY 21.07 M, actual EPS CNY -0.1182

SHANGHAI SERUM BIO-TECHNOLOGY released FY2025 earnings on February 26 Pre-Market (BJT), actual revenue CNY 196.21 M, actual EPS CNY 0.48

Shanghai Serum Bio-Technology released FY2025 9 Months Earnings on October 27 Pre-Market (BJT), actual revenue CNY 175.14 M, actual EPS CNY 0.6317

SHANGHAI SERUM BIO-TECHNOLOGY released FY2025 Q3 earnings on October 27 Pre-Market (BJT), actual revenue CNY 74.32 M, actual EPS CNY 0.2928

SHANGHAI SERUM BIO-TECHNOLOGY to Release FY2025 Q3 Earnings on October 28, 2025 Pre-Market BJT

SHANGHAI SERUM BIO-TECHNOLOGY released FY2025 Q2 earnings on August 25 During-Market (BJT), actual revenue CNY 75.2 M, actual EPS CNY 0.3088

SHANGHAI SERUM BIO-TECHNOLOGY released FY2025 Semi-Annual Earnings on August 25 During-Market (BJT), actual revenue CNY 100.82 M, actual EPS CNY 0.3

SHANGHAI SERUM BIO-TECHNOLOGY to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Selun Biopharma Elaborates on Antivenom Market Potential and Application Scenarios

Sailen Biopharma Responds to Product Export and Rabies Serum Launch Progress

Selan Biopharma Developing Rapid Snake Venom Diagnostic Reagents

Shanghai Serum Bio-Technology released FY2025 Q1 earnings on April 25 After-Market BJT, actual revenue CNY 25.62 M, actual EPS CNY 0.03

Shanghai Serum Bio-Technology FY2025 Q1 Earnings Release on April 26 After-Market BJT

Shanghai Serum Bio-Technology to Release FY2024 Earnings Report on April 26, 2025 (BJT)

SHANGHAI SERUM BIO-TECHNOLOGY released FY2024 Q4 earnings on February 25, 2025 (BJT), with actual revenue of CNY 21.62 M and EPS of CNY -0.1751

SHANGHAI SERUM BIO-TECHNOLOGY released FY2024 annual earnings on February 25 (BJT), actual revenue CNY 194.92 M, actual EPS CNY 0.41

Sirun Biologics Suspends Clinical Research on Anmei Monoclonal Antibody and Provisions for Impairment of 14.1448 Million Yuan

688163

According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY disclosed its third-quarter report for 2025. The company achieved revenue of 175 million yuan in the first three quarters, a year-on-year increase of 1.07%; net profit attributable to shareholders was 64.21 million yuan, a year-on-year increase of 2.01%; net profit excluding non-recurring items was 56.44 million yuan, a year-on-year increase of 12.15%; basic earnings per share were 0.59 yuan

Zhitong

SHANGHAI SERUM BIO-TECHNOLOGY released its performance for the first three quarters, with a net profit attributable to the parent company of 64.21 million yuan, a year-on-year increase of 2.01%

002036

301110

On September 11th, a total of 3 listed companies had their restricted shares unlocked, with a total market value of approximately 2.038 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares LCE 002036 Equity Incentive Restricted Circulation 50,000 QINGMU 301110 Extended Restricted Lock-up Period Circulation 30.75 million SHANGHAI SERUM BIO-TECHNOLOGY 688163 6.3848 million

QINGMU

Zhitong A-share lock-up release overview | September 11

According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 101 million yuan, a year-on-year increase of 2.82%; net profit attributable to shareholders was 32.98 million yuan, a year-on-year increase of 2.07%; net profit excluding non-recurring items was 28.53 million yuan, a year-on-year increase of 25.08%; basic earnings per share were 0.30 yuan. The company plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders

SHANGHAI SERUM BIO-TECHNOLOGY released its semi-annual performance, with a net profit attributable to the parent company of 32.98 million yuan, a year-on-year increase of 2.07%

SHANGHAI SERUM BIO-TECHNOLOGY stated on the interactive platform that the company has not conducted any research related to AIDS vaccines

SHANGHAI SERUM BIO-TECHNOLOGY: Has not conducted research related to AIDS vaccines

600883

301167

According to data from Data Treasure, 21 non-ST stocks have a market value of less than 2 billion yuan, and their debt-to-asset ratio is below 40% at the end of the first quarter, with positive net profits for both 2024 and the first quarter of this year. Among them, Qilu Huaxin and Hengyu Environmental Protection have market values of less than 1.5 billion yuan, while SHANGHAI SERUM BIO-TECHNOLOGY and YBTI have the lowest debt-to-asset ratios, both below 10%. SHANGHAI SERUM BIO-TECHNOLOGY mainly engages in antitoxin and antiserum, while YBTI is involved in edible mushrooms, ham, and coffee businesses. AADRI's net profit surged nearly 28 times year-on-year, mainly engaged in architectural design and consulting

YBTI

AADRI

Niutech

CNI BIOMEDICINE

Environment Protection

SINOPEC CORP

"Small and Beautiful" Stocks Exposed, 21 Stocks Listed

SHANGHAI SERUM BIO-TECHNOLOGY released its 2024 annual performance report, with total operating revenue of 195 million yuan, a year-on-year increase of 2.51%; net profit attributable to the parent company's owners was 45.3956 million yuan, a year-on-year increase of 17.08%; net profit excluding non-recurring gains and losses was 29.3550 million yuan, a year-on-year increase of 22.30%; basic earnings per share were 0.42 yuan. The company focuses on its main business, market expansion, increased product sales and output, stable growth in operating revenue, recovery in gross profit margin, and a year-on-year decrease in R&D expenses

SHANGHAI SERUM BIO-TECHNOLOGY's net profit for the year 2024 is 45.3956 million yuan, a year-on-year increase of 17.08%

SHANGHAI SERUM BIO-TECHNOLOGY announced that Chief Financial Officer Li Shaoyang resigned for personal reasons and will no longer hold any position in the company after his resignation. The company's board of directors held a meeting on February 7, 2025, and appointed Liu Jinbao as the new Chief Financial Officer, with a term until the end of the fourth board's term

SHANGHAI SERUM BIO-TECHNOLOGY: Appointed Liu Jinbao as Chief Financial Officer

SHANGHAI SERUM BIO-TECHNOLOGY(688163.SH)